Synapse Open Synapse
General knowledge

In a late-stage trial, personalized mRNA vaccines for...

Kottke · · 1 min read

In a late-stage trial, personalized mRNA vaccines for melanoma “reduced the risk of death or recurrence by 42 percent compared to standard treatment” .

Latest from Kottke